IGC Pharma (NYSEAMERICAN:IGC) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of IGC Pharma (NYSEAMERICAN:IGC) in a research note published on Monday. The brokerage issued a sell rating on the construction company’s stock.

IGC Pharma Trading Up 6.4 %

NYSEAMERICAN:IGC opened at $0.54 on Monday. IGC Pharma has a one year low of $0.25 and a one year high of $0.91. The stock has a market capitalization of $35.94 million, a P/E ratio of -2.07 and a beta of 1.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.86 and a current ratio of 1.85.

IGC Pharma (NYSEAMERICAN:IGC) last announced its quarterly earnings data on Wednesday, February 14th. The construction company reported ($0.09) earnings per share for the quarter. IGC Pharma had a negative net margin of 1,163.24% and a negative return on equity of 110.37%. The firm had revenue of $0.20 million during the quarter.

Institutional Investors Weigh In On IGC Pharma

An institutional investor recently raised its position in IGC Pharma stock. Commonwealth Equity Services LLC raised its position in IGC Pharma, Inc. (NYSEAMERICAN:IGC) by 211.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 165,490 shares of the construction company’s stock after purchasing an additional 112,334 shares during the quarter. Commonwealth Equity Services LLC owned about 0.31% of IGC Pharma worth $59,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 3.87% of the company’s stock.

IGC Pharma Company Profile

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.